請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69192
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 翁啟惠(Chi-Huey Wong) | |
dc.contributor.author | Woan-Mei Jean | en |
dc.contributor.author | 簡婉玫 | zh_TW |
dc.date.accessioned | 2021-06-17T03:10:21Z | - |
dc.date.available | 2023-08-01 | |
dc.date.copyright | 2018-08-01 | |
dc.date.issued | 2018 | |
dc.date.submitted | 2018-07-18 | |
dc.identifier.citation | 1. Padma, V. V., An overview of targeted cancer therapy. BioMedicine- Taiwan 2015, 5 (4), 1-6.
2. Sawyers, C., Targeted cancer therapy. Nature 2004, 432 (7015), - 297. 3. Harris, M., Monoclonal antibodies as therapeutic agents for cancer. Lancet Oncol. 2004, 5 (5), 292-302. 4. Carter, P.; Presta, L.; Gorman, C. M.; Ridgway, J. B. B.; Henner, D.; Wong, W. L. T.; Rowland, A. M.; Kotts, C.; Carver, M. E.; Shepard, H. M., HUMANIZATION OF AN ANTI-P185HER2 ANTIBODY FOR HUMAN CANCER-THERAPY. Proc. Natl. Acad. Sci. U. S. A. 1992, 89 (10), 4285-4289. 5. Allen, T. M., Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2 (10), 750-763. 6. Lee, T. Y.; Wu, H. C.; Tseng, Y. L.; Lin, C. T., A novel peptide specifically binding to nasopharyngeal carcinoma for targeted drug delivery. Cancer Res. 2004, 64 (21), 8002-8008. 7. Sapra, P.; Allen, T. M., Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes. Clin. Cancer Res. 2004, 10 (7), 2530-2537. 8. Cohen, P., The development and therapeutic potential of protein kinase inhibitors. Curr. Opin. Chem. Biol. 1999, 3 (4), 459-465. 9. Cohen, P., Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 2002, 1 (4), 309-315. 10. Dancey, J.; Sausville, E. A., Issues and progress with protein kinase inhibitors for cancer treatment. Nat. Rev. Drug Discov. 2003, 2 (4), 296-313. 11. Varki, A., Essentials of Glycobiology. 2015. 12. Varki, A., Biological roles of glycans. Glycobiology 2017, 27 (1), 3- 49. 13. Rodriguez, E.; Schetters, S. T. T.; van Kooyk, Y., The tumour glyco- code as a novel immune checkpoint for immunotherapy. Nat. Rev. Immunol. 2018, 18 (3), 204-211. 14. Ghazarian, H.; Idoni, B.; Oppenheimer, S. B., A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem. 2011, 113 (3), 236-247. 15. Heimburg-Molinaro, J.; Lum, M.; Vijay, G.; Jain, M. T.; Almogren, A.; Rittenhouse-Olson, K., Cancer vaccines and carbohydrate epitopes. Vaccine 2011, 29 (48), 8802-8826. 16. Ugorski, M.; Laskowska, A., Sialyl Lewis(a): a tumor-associated carbohydrate antigen involved in adhesion and metastatic potential of cancer cells. Acta Biochim. Pol. 2002, 49 (2), 303-311. 17. Xu, Y. F.; Sette, A.; Sidney, J.; Gendler, S. J.; Franco, A., Tumor- associated carbohydrate antigens: A possible avenue for cancer prevention. Immunol. Cell Biol. 2005, 83 (4), 440-448. 18. Anagnostou, V. K.; Brahmer, J. R., Cancer Immunotherapy: A Future Paradigm Shift in the Treatment of Non-Small Cell Lung Cancer. Clin. Cancer Res. 2015, 21 (5), 976-984. 19. Buskas, T.; Thompson, P.; Boons, G. J., Immunotherapy for cancer: synthetic carbohydrate-based vaccines. Chemical Communications 2009, (36), 5335-5349. 20. Drake, C. G.; Lipson, E. J.; Brahmer, J. R., Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat. Rev. Clin. Oncol. 2014, 11 (1), 24-37. 21. Melief, C. J. M.; van Hall, T.; Arens, R.; Ossendorp, F.; van der Burg, S. H., Therapeutic cancer vaccines. J. Clin. Invest. 2015, 125 (9), 3401-3412. 22. Song, Q.; Zhang, C. D.; Wu, X. H., Therapeutic cancer vaccines: From initial findings to prospects. Immunol. Lett. 2018, 196, 11-21. 23. Feng, D. Y.; Shaikh, A. S.; Wang, F. S., Recent Advance in Tumor- associated Carbohydrate Antigens (TACAs)-based Antitumor Vaccines. ACS Chem. Biol. 2016, 11 (4), 850-863. 24. Campos, M.; Godson, D. L., The effectiveness and limitations of immune memory: understanding protective immune responses. Int. J. Parasit. 2003, 33 (5-6), 655-661. 25. Danishefsky, S. J., From the laboratory to the clinic: A retrospective on fully synthetic carbohydrate-based anticancer vaccines. Abstr. Pap. Am. Chem. Soc. 2000, 219, U131-U131. 26. Germain, R. N.; Margulies, D. H., THE BIOCHEMISTRY AND CELL BIOLOGY OF ANTIGEN PROCESSING AND PRESENTATION. Annu. Rev. Immunol. 1993, 11, 403-450. 27. Kennedy, R.; Celis, E., Multiple roles for CD4(+) T cells in anti- tumor immune responses. Immunol. Rev. 2008, 222, 129-144. 28. Buskas, T.; Ingale, S.; Boons, G. J., Towards a fully synthetic carbohydrate-based anticancer vaccine: Synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated Tn antigen. Angew. Chem.-Int. Edit. 2005, 44 (37), 5985-5988. 29. Buskas, T.; Li, Y. H.; Boons, G. J., The immunogenicity of the tumor- associated antigen Lewis(y) may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein. Chem.-Eur. J. 2004, 10 (14), 3517-3524. 30. Chentoufi, A. A.; Nesburn, A. B.; BenMohamed, L., Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer. Arch. Immunol. Ther. Exp. 2009, 57 (6), 409- 423. 31. Renaudet, O.; BenMohamed, L.; Dasgupta, G.; Bettahi, I.; Dumy, P., Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem 2008, 3 (5), 737-741. 32. Fan, Y. C.; Moon, J. J., Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines 2015, 3 (3), 662-685. 33. Hu, Q. L.; Wu, M.; Fang, C.; Cheng, C. Y.; Zhao, M. M.; Fang, W. H.; Chu, P. K.; Ping, Y.; Tang, G. P., Engineering Nanoparticle- Coated Bacteria as Oral DNA Vaccines for Cancer Immunotherapy. Nano Lett. 2015, 15 (4), 2732-2739. 34. Krishnamachari, Y.; Geary, S. M.; Lemke, C. D.; Salem, A. K., Nanoparticle Delivery Systems in Cancer Vaccines. Pharm. Res. 2011, 28 (2), 215-236. 35. Cobb, B. A.; Kasper, D. L., Zwitterionic capsular polysaccharides: the new MHCII-dependent antigens. Cell Microbiol. 2005, 7 (10), 1398- 1403. 36. De Silva, R. A., Wang, Q., Chidley, T., Appulage, D. K., and Andreana, P. R., Immunological response from an entirely carbohydrate antigen: design of synthetic vaccines based on Tn-PS A1 conjugates. J. Am. Chem. Soc. 2009, 131, 9622−9623. 37. Wang, Q.; McLoughlin, R. M.; Cobb, B. A.; Charrel-Dennis, M.; Zaleski, K. J.; Golenbock, D.; Tzianabos, A. O.; Kasper, D. L., A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J. Exp. Med. 2006, 203 (13), 2853-2863. 38. Alves, F.; Borchers, U.; Keim, H.; Fortte, R.; Olschimke, J.; Vogel, W. F.; Halfter, H.; Tietze, L. F., Inhibition of EGF-mediated receptor activity and cell proliferation by HK1-ceramide, a stable analog of the ganglioside GM3-lactone. Glycobiology 2002, 12 (8), 517-522. 39. Huang, Y. L.; Hung, J. T.; Cheung, S. K. C.; Lee, H. Y.; Chu, K. C.; Li, S. T.; Lin, Y. C.; Ren, C. T.; Cheng, T. J. R.; Hsu, T. L.; Yu, A. L.; Wu, C. Y.; Wong, C. H., Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer. Proc. Natl. Acad. Sci. U. S. A. 2013, 110 (7), 2517-2522. 40. Chapman, P. B.; Morrissey, D. M.; Panageas, K. S.; Hamilton, W. B.; Zhan, C.; Destro, A. N.; Williams, L.; Israel, R. J.; Livingston, P. O., Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin+QS21 vaccine: A dose-response study. Clin. Cancer Res. 2000, 6 (3), 874- 879. 41. Eggermonf, A. M. M., Therapeutic vaccines in solid tumours: Can they be harmful? Eur. J. Cancer 2009, 45 (12), 2087-2090. 42. Kagan, E.; Ragupathi, G.; Yi, S. S.; Reis, C. A.; Gildersleeve, J.; Kahne, D.; Clausen, H.; Danishefsky, S. J.; Livingston, P. O., Comparison of antigen constructs and carrier molecules for augmenting the immunogenicity of the monosaccharide epithelial cancer antigen Tn. Cancer Immunol. Immunother. 2005, 54 (5), 424- 430. 43. Slovin, S. F.; Ragupathi, G.; Musselli, C.; Fernandez, C.; Diani, M.; Verbel, D.; Danishefsky, S.; Livingston, P.; Scher, H. I., Thomsen- Friedenreich (TF) antigen as a target for prostate cancer vaccine: clinical trial results with TF cluster (c)-KLH plus QS21 conjugate vaccine in patients with biochemically relapsed prostate cancer. Cancer Immunol. Immunother. 2005, 54 (7), 694-702. 44. Sabbatini, P. J.; Ragupathi, G.; Hood, C.; Aghajanian, C. A.; Juertzka, M.; Lasonos, A.; Hensley, M. L.; Spassova, M. K.; Ouerfelli, O.; Spriggs, D. R.; Tew, W. P.; Konner, J.; Clausen, H.; Abu Rustum, N.; Dansihefsky, S. J.; Livingston, P. O., Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin. Cancer Res. 2007, 13 (14), 4170-4177. 45. Parry, A. L.; Clemson, N. A.; Ellis, J.; Bernhard, S. S. R.; Davis, B. G.; Cameron, N. R., 'Multicopy Multivalent' Glycopolymer-Stabilized Gold Nanoparticles as Potential Synthetic Cancer Vaccines. J. Am. Chem. Soc. 2013, 135 (25), 9362-9365. 46. Cai, L., Recent Progress in Enzymatic Synthesis of Sugar Nucleotides. J. Carbohydr. Chem. 2012, 31 (7), 535-552. 47. Hsu, C. H.; Hung, S. C.; Wu, C. Y.; Wong, C. H., Toward Automated Oligosaccharide Synthesis. Angew. Chem.-Int. Edit. 2011, 50 (50), 11872-11923. 48. Schmaltz, R. M.; Hanson, S. R.; Wong, C. H., Enzymes in the Synthesis of Glycoconjugates. Chem. Rev. 2011, 111 (7), 4259-4307. 49. Krasnova, L.; Wong, C. H., Understanding the Chemistry and Biology of Glycosylation with Glycan Synthesis. In Annual Review of Biochemistry, Vol 85, Kornberg, R. D., Ed. Annual Reviews: Palo Alto, 2016; Vol. 85, pp 599-630. 50. Muthana, S.; Cao, H. Z.; Chen, X., Recent progress in chemical and chemoenzymatic synthesis of carbohydrates. Curr. Opin. Chem. Biol. 2009, 13 (5-6), 573-581. 51. Wong, C.-H., Enzymatic and chemo-enzymatic synthesis of carbohydrates. Pure & Appl. Chem. 1995, 67, 1609-1616. 52. Chi-Huey Wong, S. L. H. G. M. W., Enzyme-Catalyzed Synthesis of IV-Acetyllactosamine with in Situ Regeneration of Uridine S'- Diphosphate Glucose and Uridine S'-Diphosphate Galactose. The Journal of Organic Chemistry 1982, 47, 5416-5418. 53. Michael D. Burkart, M. I., and Chi-Huey Wong, Enzymatic Regeneration of 39-Phosphoadenosine-59-Phosphosulfate Using Aryl Sulfotransferase for the Preparative Enzymatic Synthesis of Sulfated Carbohydrates. Angew. Chem. Int. Ed. 1999. 54. Mackenzie, L. F.; Wang, Q. P.; Warren, R. A. J.; Withers, S. G., Glycosynthases: Mutant glycosidases for oligosaccharide synthesis. J. Am. Chem. Soc. 1998, 120 (22), 5583-5584. 55. Nakai, H.; Kitaoka, M.; Svensson, B.; Ohtsubo, K., Recent development of phosphorylases possessing large potential for oligosaccharide synthesis. Curr. Opin. Chem. Biol. 2013, 17 (2), 301- 309. 56. O'Neill, E. C.; Field, R. A., Enzymatic synthesis using glycoside phosphorylases. Carbohydr. Res. 2015, 403, 23-37. 57. Zhou, D. P.; Henion, T. R.; Jungalwala, F. B.; Berger, E. G.; Hennet, T., The beta 1,3-galactosyltransferase beta 3GalT-V is a stage-specific embryonic antigen-3 (SSEA-3) synthase. J. Biol. Chem. 2000, 275 (30), 22631-22634. 58. Chang, W. W.; Lee, C. H.; Lee, P. S.; Lin, J. W.; Hsu, C. W.; Hung, J. T.; Lin, J. J.; Yu, J. C.; Shao, L. E.; Yu, J.; Wong, C. H.; Yu, A. L., Expression of Globo H and SSEA3 in breast cancer, stem cells and the involvement of fucosyl transferases 1 and 2 in Globo H synthesis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105 (33), 11667-11672. 59. Lou, Y. W.; Wang, P. Y.; Yeh, S. C.; Chuang, P. K.; Li, S. T.; Wu, C. Y.; Khoo, K. H.; Hsiao, M.; Hsu, T. L.; Wong, C. H., Stage-specific embryonic antigen-4 as a potential therapeutic target in glioblastoma multiforme and other cancers. Proc. Natl. Acad. Sci. U. S. A. 2014, 111 (7), 2482-2487. 60. Zhou, D. P.; Mattner, J.; Cantu, C.; Schrantz, N.; Yin, N.; Gao, Y.; Sagiv, Y.; Hudspeth, K.; Wu, Y. P.; Yamashita, T.; Teneberg, S.; Wang, D. C.; Proia, R. L.; Levery, S. B.; Savage, P. B.; Teyton, L.; Bendelac, A., Lysosomal glycosphingolipid recognition by NKT cells. Science 2004, 306 (5702), 1786-1789. 61. Porubsky, S.; Speak, A. O.; Luckow, B.; Cerundolo, V.; Platt, F. M.; Grone, H. J., Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (14), 5977-5982. 62. Christiansen, D.; Milland, J.; Mouhtouris, E.; Vaughan, H.; Pellicci, D. G.; McConville, M. J.; Godfrey, D. I.; Sandrin, M. S., Humans lack iGb3 due to the absence of functional iGb3-synthase: Implications for NKT cell development and transplantation. PLoS. Biol. 2008, 6 (7), 1527-1538. 63. Speak, A. O.; Salio, M.; Neville, D. C. A.; Fontaine, J.; Priestman, D. A.; Platt, N.; Heare, T.; Butters, T. D.; Dwek, R. A.; Trottein, F.; Exley, M. A.; Cerundolo, V.; Platt, F. M., Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals. Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (14), 5971-5976. 64. Godfrey, D. I.; Pellicci, D. G.; Patel, O.; Kjer-Nielsen, L.; McCluskey, J.; Rossjohn, J., Antigen recognition by CD1d-restricted NKT T cell receptors. Semin. Immunol. 2010, 22 (2), 61-67. 65. Porubsky, S.; Speak, A. O.; Salio, M.; Jennemann, R.; Bonrouhi, M.; Zafarulla, R.; Singh, Y.; Dyson, J.; Luckow, B.; Lehuen, A.; Malle, E.; Muthing, J.; Platt, F. M.; Cerundolo, V.; Grone, H. J., Globosides but Not Isoglobosides Can Impact the Development of Invariant NKT Cells and Their Interaction with Dendritic Cells. J. Immunol. 2012, 189 (6), 3007-3017. 66. Joseph P. Sanderson, P. J. B., Salah Mansour, Gediminas Matulis, Onisha Patel, Nikolai Lissin, Dale I. Godfrey, Kazuyoshi Kawahara, Ulrich Zähringer, Jamie Rossjohn, Michael B. Brenner, and Stephan D. Gadola, Differences in CD1d protein structure determine species- selective antigenicity of isoglobotrihexosylceramide (iGb3) to invariant natural killer T (iNKT)Cells. Eur J Immunol. 2013, 815-825. 67. Vadori, M.; Cozzi, E., Immunological Challenges and Therapies in Xenotransplantation. Cold Spring Harb. Perspect. Med. 2014, 4 (4), 19. 68. Anderson, B. L.; Teyton, L.; Bendelac, A.; Savage, P. B., Stimulation of Natural Killer T Cells by Glycolipids. Molecules 2013, 18 (12), 15662-15688. 69. Butler, J. R.; Skill, N. J.; Priestman, D. L.; Platt, F. M.; Li, P.; Estrada, J. L.; Martens, G. R.; Ladowski, J. M.; Tector, M.; Tector, A. J., Silencing the porcine iGb3s gene does not affect Gal alpha 3Gal levels or measures of anticipated pig-to-human and pig-to-primate acute rejection. Xenotransplantation 2016, 23 (2), 106-116. 70. Adeline Miermont, Y. Z., Yuqing Jing, Xin-shan Ye, and Xuefei Huang, Syntheses of LewisX and Dimeric LewisX: Construction of Branched Oligosaccharides by a Combination of Pre-activation and Reactivity Based Chemoselective One-Pot Glycosylations. J Org Chem. 2007, 8958-8961. 71. Tsai, T. I.; Lee, H. Y.; Chang, S. H.; Wang, C. H.; Tu, Y. C.; Lin, Y. C.; Hwang, D. R.; Wu, C. Y.; Wong, C. H., Effective Sugar Nucleotide Regeneration for the Large-Scale Enzymatic Synthesis of Globo H and SSEA4. J. Am. Chem. Soc. 2013, 135 (39), 14831- 14839. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/69192 | - |
dc.description.abstract | 現有的癌症藥物由於專一性不足,在攻擊癌症細胞的同時,亦會造成大量的 正常細胞死亡,引起強烈的副作用。近年來,有許多研究團隊致力於發展具有高 專一性的癌症藥物,以降低治療時所產生的副作用,同時提升疾病治癒率。
SSEA-3、SSEA-4 以及 Globo H 為在多種癌症細胞上具有高表現度的醣抗原, 且在正常細胞中並未被發現,因此這三種抗原可用來作為藥物辨識癌症細胞的標 的物。本實驗室先前研發的 Globo H-DT 疫苗即可誘發針對 SSEA-3、SSEA-4 及 Globo H 三種醣抗原之抗體,引起自體免疫反應,以消滅癌症細胞。 近年研究發現,在豬隻以及小鼠的體內都有 iso-Gb3 抗原的存在,此抗原的 結構與 Gb3 極為相近,其差異僅在還原端半乳糖單醣的接合位置,Gb3 是利用 α1-4 鍵結乳糖上的半乳糖,而 iso-Gb3 則是利用 α1-3 鍵結。為了釐清人體內是 否有 iso-Globo 系列抗原的存在,本篇論文利用化學結合生物酵素合成的方法, 取得 iso-Globo H 以及 iso-SSEA-4 之標準品,用以比對人體細胞與癌症細胞中是 否有 iso-Globo H 或 iso-SSEA-4 抗原之存在。其次,我們亦藉由合成的 iso-Globo 系列抗原來了解 Globo-H 以及 SSEA-4 抗體是否會辨認 iso-Globo H 與 iso-SSEA- 4 抗原,以確定此系列抗體的專一性。 本篇論文的目的在於發展更快速且更有效率合成 iso-Globo H 以及 iso-SSEA- 4 的路徑,以協助我們了解 iso-Globo 系列抗原是否有參與在癌症疾病發展的行 為中,同時測試抗體對於 Globo 系列抗原以及 iso-Globo 系列抗原的辨別能力。 透過本篇論文的研究,我們期許能更了解癌症發展的機制,以優化我們所研發的 癌症疫苗,同時開發新的治療方法。 | zh_TW |
dc.description.abstract | The presence of non-specific activity in the conventional cancer drugs often damage both cancer cells and normal cells at the same time and, thus, cause severe side effect. To reduce the side effect and boost the efficacy, many research teams devote great efforts in developing new anti-cancer drugs with high specificity.
The glyco-antigens, SSEA-3, SSEA-4 and Globo H, are overexpressed on cancer cells but not on normal cells and, thus, can be used as targets to distinguish between normal cells and cancer cells for the development of anti-cancer drugs. The Globo H-DT vaccine developed in our laboratory for cancer treatment in 2013 is capable of simultaneously inducing immune response and eliciting antibodies against SSEA-3, SSEA-4 and Globo H. The iso-Gb3 antigen was found in pigs and murine. The structure of this antigen is very similar to that of Gb3. The difference is only at the linkage of the galactose monosaccharide at the Cl-position. Gb3 is a terminal galactose α1-4 links to lactose, and iso-Gb3 is α1-3 linkage. In this study, the chemoenzymatic methods were applied to rapidly and efficiently synthesize iso-Globo H and iso-SSEA-4 as standards to clarify whether iso-Globo series antigens are expressed on normal and/or cancer cells and to test whether Globo H and SSEA-4 antibodies can recognize the iso- Globo series antigens. Our results suggested anti-Globo series antibodies could distinguish between Globo series and iso-Globo series antigens and demonstrated how iso-Globo series glycans are involved in cancer progression. | en |
dc.description.provenance | Made available in DSpace on 2021-06-17T03:10:21Z (GMT). No. of bitstreams: 1 ntu-107-R05223102-1.pdf: 3134933 bytes, checksum: a2e56260d446d547c3a66248ea3fba18 (MD5) Previous issue date: 2018 | en |
dc.description.tableofcontents | 口試委員會審定書............................................................ i
謝誌 ...................................................ii 中文摘要 ..............................................iii Abstract ................................................iv CONTENTS .............................................v LIST OF FIGURES .....................................vii LIST OF TABLES .....................................viii LIST OF SCHEME ......................................ix Chapter 1 Introduction.....................................1 1.1 Background ....................................................................... 1 1.2 The importance of glycans in organism........................................... 2 1.3 Carbohydrates in cancer disease .................................... 4 1.3.1 Tumor associated carbohydrate antigens................ 5 1.3.2 Mechanism of cancer vaccine immunotherapy ................... 7 1.3.3 Recent development in TACA-based cancer vaccines .......... 8 1.4 Enzymatic synthesis of TACAs................. 11 1.4.1 Enzymatic synthesis using glycosyltransferases (GTs) ...................... 12 1.4.2 Enzymatic synthesis using glycosyl hydrolases (GHs) and glycosyl synthase (GS).................................................... 13 1.5 Biological properties of Globo series in cancer development.......... 13 1.5.1 Biological synthesis of Globo series........................ 14 1.5.2 Expression rates of Globo series in different types of cancer.......... 15 1.6 Previous researches in iso-Gb3...................... 16 1.7Objectives..................................................... 17 Chapter 2 Results and Discussion ...........................19 2.1 Chemical synthesis of iso-Gb3 ................... 19 2.1.1 Retro-synthesis of iso-Gb3 .................... 19 2.1.2 Synthesis of lactose building block............... 20 2.1.3 Synthesis of galactose building block .............. 23 2.1.4 Glycosylation between Lactose- and Galactose Building Block ....................... 25 2.2 Enzymatic synthesis of iGb3 ................... 27 2.2.1 Enzymatic synthesis from iGb3 to iGlobo H and iSSEA-4........ 28 Chapter 3 Conclusion .....................................33 Chapter 4 Experiment Section ..............................34 4.1 General Method............................... 34 4.2 Experiment Section ........................... 35 REFERENCE .....................................55 | |
dc.language.iso | en | |
dc.title | Globo 系列抗原異構物之合成與 Globo 系列抗體專一性之研究 | zh_TW |
dc.title | Synthesis of Iso-Globo Series and the Specificity Study on Globo Series Recognized Antibodies | en |
dc.type | Thesis | |
dc.date.schoolyear | 106-2 | |
dc.description.degree | 碩士 | |
dc.contributor.coadvisor | 吳宗益(Chung-Yi Wu) | |
dc.contributor.oralexamcommittee | 謝俊結 | |
dc.subject.keyword | 癌症疫苗,酵素合成,癌症相關醣抗原, | zh_TW |
dc.subject.keyword | cancer vaccine,enzymatic synthesis,tumor associated carbohydrate antigen (TACA), | en |
dc.relation.page | 91 | |
dc.identifier.doi | 10.6342/NTU201801507 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2018-07-19 | |
dc.contributor.author-college | 理學院 | zh_TW |
dc.contributor.author-dept | 化學研究所 | zh_TW |
顯示於系所單位: | 化學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-107-1.pdf 目前未授權公開取用 | 3.06 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。